Literature DB >> 28370308

Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time.

Adrian Heald1,2, Mark Livingston3, Alison Yung4, M A De Hert5.   

Abstract

INTRODUCTION: Diabetes, obesity, and metabolic syndrome are highly prevalent in patients with severe mental illness. Psychotropic polypharmacy is becoming increasingly prevalent within the UK. We determined the change in the number of psychotropic medications prescribed over time and trends in weight and fasting blood glucose.
METHODS: One hundred ninety-five individuals with schizophrenia and psychosis on the Severe Mental Illness Register in Cheshire, UK, were followed up between 2004 and 2012. Individuals were identified through a semianonymised search of general practitioner registers.
RESULTS: The total number of different medications prescribed increased from 140 in 2004 to 226 in 2012 with the mean number of medication groups per patient increasing from 0.71 to 1.15 (p < .001). The number of individuals on no medication reduced from 58.0% to 33.3%, OR 0.36 95% CI [0.24, 0.54], and those prescribed one medication increased from 20.5% to 31.8%, OR 1.93 95% CI [1.22-3.06]. Baseline body mass index was 28.9, increasing to 30.8 at 8-year follow-up, F(6.5), p = .003, with a significant corresponding increase in fasting blood glucose.
CONCLUSION: In conclusion, we determined an increase in psychotropic polypharmacy over the follow-up period. Body mass index or fasting blood glucose increased over time. Clozapine and depot antipsychotic prescriptions were often not recorded in the general practitioner records.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  BMI; prescribing; psychosis; psychotropic; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28370308     DOI: 10.1002/hup.2579

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

Review 1.  [Psychiatric pharmacotherapy of older individuals with severe mental illness].

Authors:  Christian Lange-Asschenfeldt
Journal:  Z Gerontol Geriatr       Date:  2018-10-09       Impact factor: 1.281

2.  Clozapine Patients at the Interface between Primary and Secondary Care.

Authors:  Marita Barrett; Anna Keating; Deirdre Lynch; Geraldine Scanlon; Mary Kigathi; Fidelma Corcoran; Laura J Sahm
Journal:  Pharmacy (Basel)       Date:  2018-02-26

3.  Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.

Authors:  Esra Yazici; Ali S Cilli; Ahmet B Yazici; Hayriye Baysan; Mustafa Ince; Sukriye Bosgelmez; Serkan Bilgic; Betul Aslan; Atila Erol
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-08-11

4.  Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study.

Authors:  Sermin Toto; Renate Grohmann; Stefan Bleich; Helge Frieling; Hannah B Maier; Waldemar Greil; Joachim Cordes; Christian Schmidt-Kraepelin; Siegfried Kasper; Susanne Stübner; Detlef Degner; Katrin Druschky; Tristan Zindler; Alexandra Neyazi
Journal:  Int J Neuropsychopharmacol       Date:  2019-09-01       Impact factor: 5.176

5.  Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection.

Authors:  A H Heald; M Stedman; S Farman; C Khine; M Davies; M De Hert; D Taylor
Journal:  BMC Psychiatry       Date:  2020-11-07       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.